Share on LinkedInShare on LinkedIn

ARTICLE · 06 APRIL 2020

Patent Eligible Method Of Treatment/Prevention Claim

治療方法クレームの101条特許適格性を認めた判例としてVanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Ltd., 887 F.3d 1117 (Fed. Cir. 2018)があります

United StatesIntellectual Property

特許適格性を満たす治療/予防方法クレーム の例

治療方法クレームの101条特許適格性を認めた判例として Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Ltd., 887 F.3d 1117 (Fed. Cir. 2018)があります。この判例に沿ってCAFCは、本件 Boehringer Ingelheim Pharmaceuticals Inc. v. Mylan Pharmaceuticals Inc. et al., No. 19-1172において、治療方法クレームの特許適格性無しとの地裁判決(grant of judgment on the pleadings)を覆し、差し戻しました(nonprecedential, 3/16/2020)。

争点となった米国特許8,853,156のクレーム10は下記の通りです。

1. A method of treating and/or preventing metabolic diseases in a patient for whom metformin therapy is inappropriate due to at least one contraindication against metformin comprising orally administering to the patient a DPP-IV inhibitor wherein the contraindication is selected from the group consisting of: renal disease, renal impairment or renal dysfunction, unstable or acute congestive heart failure, acute or chronic metabolic acidosis, and hereditary galactose intolerance.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from